CCR4 Antibody

What is CCR4 and why is it a significant research target?

CCR4 (C-C motif chemokine receptor 4) is a G-protein coupled receptor expressed primarily on T cells, particularly regulatory T cells (Tregs) and helper T cells. This protein may also be known as CD194, HGCN:14099, K5-5, CC-CKR-4, CKR4, or C-C chemokine receptor type 4. Structurally, human CCR4 is a 41.4 kilodalton protein that functions as a receptor for chemokines CCL17 and CCL22 .

CCR4 has emerged as a significant research target because of its high expression on cutaneous T-cell lymphoma (CTCL) cells and its preferential expression on Tregs. This expression pattern makes CCR4 not only a potential therapeutic target for CTCLs but also for other types of cancers in which CCR4-positive Tregs are involved in immune evasion. The skin-homing capacity of CCR4-expressing cells further enhances the relevance of this receptor in CTCL research .

Researchers have developed various anti-CCR4 antibodies that recognize different epitopes of the receptor, including the N-terminal domain and extracellular loops, each with distinct functional properties relevant to different research applications and therapeutic approaches.

How do CCR4 antibodies differ in structure and binding properties?

CCR4 antibodies can be categorized based on several structural and functional characteristics that determine their research and clinical utility. These antibodies differ in their species origin (murine, humanized, or fully human), isotype (which affects their effector functions), and epitope specificity.

For example, the murine antibody mAb1567 (available commercially from R&D systems) recognizes both the N-terminal and extracellular domains of CCR4 with high affinity. This dual recognition property enables it to inhibit chemotaxis of CCR4-expressing cells toward chemotactic ligands CCL17 and CCL22 . In contrast, the humanized antibody mogamulizumab (KW-0761) has been optimized specifically for enhanced antibody-dependent cellular cytotoxicity (ADCC) activity against CCR4-expressing cells .

The binding characteristics of CCR4 antibodies are crucial to consider when selecting an antibody for a specific research application. Antibodies recognizing different epitopes on CCR4 may have varying effects on receptor signaling, internalization, and downstream functional outcomes. Additionally, the orientation of heavy and light chain variable regions in the single-chain variable fragment (scFv) format can significantly impact binding efficiency and CAR T-cell activity, as demonstrated in comparative studies of different CCR4-CAR constructs .

What detection methods are available for measuring CCR4 expression?

Researchers can employ multiple complementary techniques to detect and quantify CCR4 expression in various sample types:

Flow Cytometry (FCM): This is the most common method for detecting CCR4 on cell surfaces. Various commercially available antibodies can be used, including conjugated versions of mogamulizumab (KW-0761) labeled with fluorophores such as Alexa Fluor 680. Detection of CCR4-CAR expression on engineered T cells can be accomplished using biotinylated anti-human Fab antibodies .

Immunohistochemistry (IHC): For tissue samples, CCR4 expression can be detected using antibodies such as the polyclonal antibody HPA031613 from Sigma-Aldrich on paraformaldehyde-fixed and paraffin-embedded samples. This technique is particularly valuable for assessing CCR4 expression in biopsy specimens from patients .

Molecular Methods: Reverse transcription PCR (RT-PCR) and quantitative PCR can be used to measure CCR4 mRNA expression levels. These techniques are particularly useful when protein detection is challenging or when examining transcriptional regulation of CCR4.

When selecting a detection method, researchers should consider factors such as sample type, required sensitivity, and whether detection of surface or intracellular CCR4 is needed. Cross-validation using multiple detection methods is recommended for critical experiments, particularly when evaluating novel therapeutic approaches targeting CCR4.

How can researchers evaluate anti-CCR4 antibody efficacy in vitro?

Evaluating the efficacy of anti-CCR4 antibodies requires a comprehensive approach that assesses multiple functional aspects. Here are key methodological approaches:

Binding Assays: Flow cytometry is commonly used to measure antibody binding to CCR4-expressing cells. Researchers typically use cell lines with known CCR4 expression (e.g., Cf2Th-CCR4 cells) compared to CCR4-negative parental lines as controls. Titration experiments should be performed to determine optimal antibody concentrations and affinity properties .

Chemotaxis Inhibition: Since CCR4 mediates migration toward its ligands CCL17 and CCL22, Transwell migration assays can be used to evaluate whether anti-CCR4 antibodies block this function. Effective antibodies should inhibit chemotaxis of CCR4-expressing cells toward these chemokines in a dose-dependent manner .

Cytotoxicity Assays: For antibodies designed to induce cell killing, several approaches can be used:

• Complement-dependent cytotoxicity (CDC) assays measure the ability of antibodies to activate complement and cause cell lysis

• Antibody-dependent cellular cytotoxicity (ADCC) assays require co-culture of target cells with effector cells (PBMCs, NK cells, or neutrophils) and the antibody of interest

• Direct killing assays assess whether the antibody has intrinsic cytotoxic activity independent of effector cells or complement

Signaling Inhibition: Calcium flux assays or phosphorylation studies of downstream signaling molecules can evaluate whether antibodies block CCR4 signaling after ligand binding.

When designing these experiments, researchers should include appropriate controls, including isotype-matched control antibodies and positive controls such as established anti-CCR4 antibodies like mogamulizumab or mAb1567.

What are the optimal protocols for developing anti-CCR4 CAR T cells?

The development of anti-CCR4 chimeric antigen receptor (CAR) T cells involves several critical steps, each requiring optimization:

scFv Selection and Design: Multiple anti-CCR4 scFvs should be evaluated, constructed from different anti-CCR4 monoclonal antibodies. Variations should include testing both heavy-to-light (H2L) and light-to-heavy (L2H) chain orientations, as these can significantly affect CAR expression and function. For example, studies have shown that scFvs derived from the humanized anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) with both H2L and L2H orientations demonstrated superior T-cell expansion compared to other constructs .

CAR Construct Design: Standard second-generation CAR backbones containing 4-1BB and CD3ζ domains have shown efficacy. These components can be cloned into lentiviral vectors for efficient T-cell transduction .

T-cell Activation and Transduction: T cells should be stimulated with anti-CD3/CD28 beads before lentiviral transduction at an appropriate multiplicity of infection (MOI). For CCR4-CAR development, an MOI of 4 has been used successfully .

Expansion and Characterization: After transduction, T cells should be expanded by adding fresh media daily or on alternate days. Important parameters to monitor include:

• CAR expression by flow cytometry using appropriate detection antibodies

• T-cell phenotype, particularly memory subset distribution

• Cell size as an indicator of activation status

• Viability throughout the expansion process

Functional Testing: Developed CAR T cells must be assessed for:

• Cytotoxicity against CCR4+ target cells

• Cytokine production upon target recognition

• Degranulation assays measuring CD107a surface expression

• Proliferation in response to target cells

Table 1: Key Parameters for Evaluating Anti-CCR4 CAR T cells

Notably, some anti-CCR4 CAR constructs demonstrate an interesting phenomenon of autoselection, where CAR-positive cells increase to nearly 100% during expansion despite initial transduction efficiencies being comparable to other constructs .

How can researchers evaluate anti-CCR4 antibody efficacy in vivo?

In vivo evaluation of anti-CCR4 antibodies requires appropriate animal models and comprehensive assessment protocols:

Model Selection: Xenograft models using immunodeficient mice (e.g., NOD/SCID/IL2rγnull) engrafted with CCR4-expressing human tumor cell lines provide a platform for evaluating antibody efficacy. For evaluating effects on immune modulation, humanized mouse models with reconstituted human immune systems may be more appropriate .

Treatment Protocol Design: Key considerations include:

• Antibody dose and schedule (typically 100-300 μg per dose, administered weekly)

• Route of administration (intravenous or intraperitoneal)

• Treatment duration

• Inclusion of appropriate control groups (isotype control antibody, vehicle control)

• Combination with other therapeutic agents when evaluating combinatorial approaches

Efficacy Endpoints:

Mechanistic Studies: Additional analyses should evaluate:

• Antibody biodistribution using labeled antibodies

• Effects on regulatory T cells in tumor and lymphoid tissues

• Changes in tumor microenvironment

• Development of resistance mechanisms

When designing in vivo studies, researchers should be aware that CCR4 expression differs between human and mouse systems, which may affect translation of findings. Additionally, the effector functions of human antibodies may not be fully recapitulated in mouse models, necessitating careful interpretation of results.

What mechanisms contribute to resistance against anti-CCR4 antibody therapies?

Despite the initial efficacy of anti-CCR4 therapies, particularly mogamulizumab, resistance frequently emerges. Understanding resistance mechanisms is crucial for developing strategies to overcome treatment failure:

Loss of CCR4 Expression: The most common mechanism of resistance to mogamulizumab in cutaneous T-cell lymphoma (CTCL) patients is the loss of CCR4 expression. Immunohistochemistry analysis of patient samples has revealed CCR4 absence in 8 out of 14 post-treatment specimens from patients with both primary and secondary resistance to mogamulizumab .

This loss of expression can occur through several molecular mechanisms:

• Mutations in the CCR4 gene affecting protein expression or antibody binding epitopes

• Downregulation of CCR4 transcription

• Selection of pre-existing CCR4-negative tumor cell populations

• Post-translational modifications affecting receptor trafficking or stability

Impaired Effector Functions: Even when CCR4 expression is maintained, resistance can develop through:

• Upregulation of complement inhibitory proteins reducing CDC efficacy

• Expression of inhibitory receptors on effector cells compromising ADCC

• Alterations in the tumor microenvironment that suppress immune effector functions

• Decreased FcγR expression or function on effector cells

Emergence of Alternative Signaling Pathways: Tumor cells may activate alternative chemokine receptor pathways to compensate for CCR4 blockade, maintaining their migration and survival capabilities.

For researchers studying resistance mechanisms, it is essential to obtain paired pre-treatment and post-resistance samples and perform comprehensive analyses including immunohistochemistry, gene expression profiling, and next-generation sequencing to identify alterations associated with treatment failure .

How does mogamulizumab compare with other anti-CCR4 therapeutic approaches?

Mogamulizumab represents the most clinically advanced anti-CCR4 therapy, but several alternative approaches are under investigation:

Mogamulizumab (KW-0761): This humanized anti-CCR4 monoclonal antibody has been FDA-approved since 2018 for treating mycosis fungoides/Sézary syndrome subtypes of CTCL. It works primarily through antibody-dependent cellular cytotoxicity (ADCC), promoting the killing of CCR4-expressing malignant T cells . Key advantages include its established safety profile and clinical experience, while limitations include the development of resistance and potential immunosuppressive effects due to depletion of CCR4+ regulatory T cells.

Anti-CCR4 CAR T Cells: This approach utilizes the patient's T cells engineered to express chimeric antigen receptors targeting CCR4. Compared to mogamulizumab, CAR T cells may provide more durable responses through persistent immunosurveillance and have shown promising results in preclinical studies . Challenges include manufacturing complexity, potential for severe toxicities, and the risk of fratricide (CAR T cells attacking each other due to CCR4 expression on activated T cells).

Bispecific Antibodies: These molecules can simultaneously target CCR4 and another tumor-associated antigen or engage T cells directly. This approach may enhance specificity and efficacy compared to monospecific antibodies like mogamulizumab.

Small Molecule CCR4 Antagonists: These compounds block CCR4 signaling rather than inducing cell death and may be useful in contexts where modulating migration is more important than cytotoxicity.

Table 2: Comparison of Anti-CCR4 Therapeutic Approaches

When evaluating these approaches, researchers should consider the specific disease context, patient population, mechanism of action, and potential combination strategies that might enhance efficacy or prevent resistance .

What biomarkers can predict response to anti-CCR4 therapies?

Identifying reliable biomarkers is essential for patient selection and treatment monitoring with anti-CCR4 therapies:

Predictive Biomarkers:

CCR4 Expression Level: The most direct biomarker is CCR4 expression on tumor cells, which can be assessed by immunohistochemistry or flow cytometry. Higher CCR4 expression generally correlates with better response to mogamulizumab, though the predictive threshold may vary by disease type .

FcγR Polymorphisms: Since mogamulizumab works primarily through ADCC, functional polymorphisms in FcγRIIIa (CD16) on effector cells can influence ADCC potency and clinical response.

Tumor Microenvironment Characteristics: The composition of immune cells in the tumor microenvironment, particularly the presence of functional NK cells and monocytes capable of mediating ADCC, may predict treatment efficacy.

Response Monitoring Biomarkers:

Circulating Tumor Cells: Quantification and phenotyping of circulating malignant cells can provide real-time assessment of treatment response and early detection of resistance.

Serum Cytokines: Changes in inflammatory cytokine levels measured by high-sensitivity assays like LUMINEX can indicate immune activation and treatment response .

Imaging Biomarkers: PET-CT using appropriate tracers can assess metabolic response and guide treatment decisions.

Resistance Monitoring:

Sequential Biopsies: Monitoring CCR4 expression during treatment can detect emerging resistance. Loss of CCR4 expression in post-treatment samples has been observed in patients who developed resistance to mogamulizumab .

Circulating Tumor DNA: Analysis of ctDNA for mutations in CCR4 or related pathway genes may provide early detection of resistance mechanisms.

The integration of multiple biomarker approaches, including baseline predictive markers and ongoing response monitoring, is likely to provide the most comprehensive strategy for optimizing anti-CCR4 therapies. Prospective clinical studies with integrated biomarker analyses are needed to validate these approaches across different disease contexts.

How can researchers address potential on-target, off-tumor toxicity of anti-CCR4 therapeutics?

CCR4 expression on normal immune cells, particularly regulatory T cells (Tregs) and certain T helper cell subsets, creates potential for on-target, off-tumor toxicity with anti-CCR4 therapeutics. Researchers are exploring several strategies to mitigate these risks:

Selective Targeting Approaches:

Affinity Modulation: Developing antibodies with carefully calibrated binding affinities that preferentially target cells with high CCR4 expression (malignant cells) while sparing cells with lower expression (normal cells). For example, researchers have developed affinity-enhanced and affinity-decreased derivatives of the humanized anti-CCR4 antibody h1567 (designated as mAb2-3 and mAb1-49, respectively) to explore this approach .

Epitope Selection: Targeting CCR4 epitopes that may be differentially accessible or post-translationally modified in tumor cells compared to normal cells.

Conditional Activation Strategies:

Split-CAR Systems: For CAR T-cell approaches, developing systems where full CAR activation requires recognition of CCR4 plus a second tumor-associated antigen.

Switchable CAR Systems: Engineering CARs that are only active in the presence of a small molecule "switch," allowing temporal control of activity.

Anatomical Restriction:

Local Administration: Delivering anti-CCR4 therapeutics directly to tumor sites to minimize systemic exposure and toxicity.

Tumor Microenvironment-Activated Agents: Developing antibody-drug conjugates or protease-activated antibodies that are fully active only in the tumor microenvironment.

Safety Mechanisms:

Suicide Genes: Incorporating inducible suicide genes in CAR T-cell products to enable elimination of cells if toxicity occurs.

mRNA-Based Approaches: Using mRNA rather than viral vectors for CAR expression, resulting in transient expression that limits the duration of potential toxicity.

Dosing Optimization:

Fractionated Dosing: Administering lower doses over time rather than a single high dose to better manage and monitor potential toxicity.

Pharmacokinetic Modification: Engineering antibodies with shorter half-lives or incorporating clearance mechanisms to limit systemic exposure.

Each of these approaches requires rigorous preclinical testing in appropriate models that recapitulate human CCR4 expression patterns across tissues. Careful clinical trial design with extensive monitoring of immune populations is essential when advancing novel anti-CCR4 therapeutics into human studies.

What are the emerging applications of anti-CCR4 antibodies beyond hematological malignancies?

While anti-CCR4 antibodies were initially developed for treating CCR4-expressing lymphomas, research is expanding their potential applications in several areas:

Solid Tumors:

CCR4+ Treg Depletion: Many solid tumors recruit CCR4+ regulatory T cells to establish an immunosuppressive microenvironment. Anti-CCR4 antibodies can deplete these Tregs, potentially enhancing anti-tumor immunity and improving responses to other immunotherapies. This approach is particularly promising for tumors with high CCR4+ Treg infiltration .

Direct Targeting: Some solid tumors, including certain breast and lung cancers, may express CCR4 directly, making them potential targets for anti-CCR4 therapies.

Inflammatory Diseases:

Allergic Disorders: CCR4 mediates recruitment of Th2 cells in allergic inflammation. Blocking this pathway could benefit conditions like asthma, atopic dermatitis, and allergic rhinitis.

Autoimmune Diseases: Modulating specific T-cell subset trafficking through CCR4 blockade may have applications in certain autoimmune conditions.

Infectious Diseases:

EBV-Associated Disorders: Research has shown that Epstein-Barr virus (EBV) can infect T and NK cells, and anti-CCR4 antibodies like mogamulizumab have been evaluated for treating EBV-associated T- and NK-cell lymphoproliferative diseases that express CCR4 .

Other Viral Infections: CCR4 may play roles in the pathogenesis of certain viral infections, offering potential therapeutic applications.

Combination Therapies:

Immune Checkpoint Inhibitors: Combining anti-CCR4 therapy with PD-1/PD-L1 or CTLA-4 blockade may enhance efficacy through complementary immune-modulating mechanisms.

Conventional Therapies: Integration with standard chemotherapy, radiation, or targeted therapies may improve outcomes across multiple cancer types.

For researchers exploring these emerging applications, careful assessment of CCR4 expression patterns in target tissues, evaluation of potential mechanisms of action, and development of appropriate preclinical models are essential steps. Biomarker strategies to identify patients most likely to benefit from anti-CCR4 approaches in these novel contexts will be particularly important for successful clinical translation.

How can novel technologies enhance anti-CCR4 antibody development and application?

Emerging technologies are transforming anti-CCR4 therapeutic development across multiple dimensions:

Antibody Engineering Advancements:

Bispecific/Multispecific Platforms: Newer platforms enable creation of antibodies targeting CCR4 along with additional targets relevant to cancer or immune modulation. These formats may enhance specificity, reduce escape mechanisms, or recruit immune effectors more effectively.

Antibody-Drug Conjugates (ADCs): Coupling anti-CCR4 antibodies with potent cytotoxic payloads could enhance tumor cell killing while potentially reducing the antibody affinity needed, thereby improving therapeutic window.

Enhanced Effector Functions: Engineering Fc modifications that optimize ADCC, ADCP, or CDC activity for specific applications, or that extend half-life through enhanced FcRn binding.

Cellular Therapy Innovations:

Next-Generation CAR Designs: Advanced CAR structures incorporating multiple costimulatory domains, inducible suicide genes, or logic-gated activation systems can enhance both efficacy and safety of anti-CCR4 CAR T-cell therapies .

Allogeneic Approaches: Off-the-shelf anti-CCR4 CAR T-cell products using gene editing to eliminate endogenous TCR and HLA could make these therapies more accessible.

Non-T Cell Effectors: Engineering NK cells, macrophages, or other immune cells with anti-CCR4 CARs may offer advantages for certain applications.

Target Validation and Patient Selection:

Single-Cell Technologies: Single-cell RNA sequencing and proteomic approaches enable precise characterization of CCR4 expression across cell types in normal and disease tissues, informing therapeutic design and patient selection.

Spatial Transcriptomics/Proteomics: These methods preserve spatial information about CCR4 expression, providing insights into its role in the tumor microenvironment architecture.

AI/Machine Learning: Computational approaches can identify patterns predicting response to anti-CCR4 therapies and suggest optimal combination strategies.

Delivery and Monitoring:

Advanced Imaging: Novel PET tracers or optical imaging approaches using labeled anti-CCR4 antibodies can monitor biodistribution and target engagement.

Nanoparticle Delivery: Encapsulating anti-CCR4 antibodies or encoding mRNAs in targeted nanoparticles could enhance delivery to specific tissues while reducing systemic exposure.

Digital Monitoring: Wearable devices and digital health tools may enable more comprehensive monitoring of response and toxicity in patients receiving anti-CCR4 therapies.

Researchers pursuing these technological innovations should consider how they address current limitations of anti-CCR4 therapeutics, particularly regarding specificity, resistance mechanisms, and delivery challenges. Collaborative approaches combining expertise in antibody engineering, cellular therapy, computational biology, and clinical development will likely yield the most impactful advances.

What are the best practices for validating CCR4 antibody specificity?

Ensuring antibody specificity is crucial for research reproducibility and therapeutic development. Researchers should implement comprehensive validation strategies:

Genetic Controls:

Knockout/Knockdown Systems: Testing antibodies on CCR4 knockout cell lines or cells with CCR4 knockdown via siRNA/shRNA provides the gold standard for specificity validation. The complete absence of signal in these systems strongly supports antibody specificity.

Overexpression Systems: Complementary to knockout approaches, testing on cells engineered to overexpress CCR4 should show enhanced signal compared to parental cells .

Epitope Characterization:

Peptide Competition: Pre-incubating antibodies with synthetic peptides corresponding to putative epitopes should block specific binding.

Domain Swapping: For conformational epitopes, creating chimeric receptors with domains from related chemokine receptors can help map binding regions.

Cross-Species Reactivity: Testing reactivity with CCR4 orthologs from different species can provide insights into epitope conservation and specificity.

Orthogonal Verification:

Multiple Antibody Clones: Comparing staining patterns of different anti-CCR4 antibodies recognizing distinct epitopes helps confirm true CCR4 detection.

Correlation with mRNA Expression: Concordance between protein detection by antibodies and mRNA levels measured by RT-PCR supports specificity.

Functional Validation:

Ligand Competition: CCR4 ligands (CCL17/CCL22) should compete with antibodies targeting the ligand-binding domain.

Functional Blockade: Antibodies targeting functional domains should inhibit chemotaxis toward CCR4 ligands or block downstream signaling like calcium flux .

Table 3: Essential Controls for CCR4 Antibody Validation

Comprehensive validation should be performed for each new lot of antibody and under the specific experimental conditions in which the antibody will be used, as fixation, permeabilization, and other processing steps can affect epitope accessibility and antibody performance.

How can researchers troubleshoot inconsistent results with anti-CCR4 antibodies?

Inconsistent results with anti-CCR4 antibodies can stem from various sources. Systematic troubleshooting approaches include:

Sample Preparation Variables:

Receptor Internalization: CCR4 can rapidly internalize upon ligand binding or antibody cross-linking. Researchers should:

• Use sodium azide or low temperatures during processing to inhibit internalization

• Consider fixation before antibody staining

• Compare results with permeabilized vs. non-permeabilized cells to detect internalized receptor

Enzymatic Dissociation: Certain enzymes used for cell isolation can cleave surface CCR4. Alternative gentle dissociation methods should be tested if this is suspected.

Fixation Effects: Different fixatives (e.g., paraformaldehyde vs. methanol) can differentially affect CCR4 epitope accessibility. Optimization of fixation protocols is essential, particularly for immunohistochemistry.

Technical Factors:

Antibody Titration: Suboptimal antibody concentrations can lead to weak signals or high background. Full titration curves should be established for each application and cell type.

Detection Systems: Secondary antibody selection, fluorophore brightness, and detection instrument settings can all impact results. Standardization of these parameters is crucial for reproducibility.

Batch Effects: Antibody lot variations can significantly impact results. Maintaining reference samples and performing side-by-side comparisons when changing lots is recommended.

Biological Variables:

Activation State: T-cell activation can modulate CCR4 expression. Researchers should standardize activation conditions or explicitly account for activation status in experiments.

Cell Type Differences: CCR4 expression levels and glycosylation patterns may vary across cell types, affecting antibody binding. Validation should be performed in each cell type of interest.

Storage and Handling: Antibody storage conditions and freeze-thaw cycles can affect performance. Following manufacturer recommendations and preparing single-use aliquots minimizes these issues.

When inconsistent results occur, researchers should implement a systematic validation approach:

• Verify antibody performance using well-characterized positive and negative control samples

• Test multiple anti-CCR4 antibody clones in parallel

• Compare results across different detection methods (flow cytometry, Western blot, immunohistochemistry)

• Carefully document all experimental conditions to identify potential variables affecting results

Through methodical troubleshooting and standardization of protocols, researchers can achieve more consistent and reliable results with anti-CCR4 antibodies across different experimental systems.